Director, Clinical Operations Asset Lead; COAL), Late Phase Lung Oncology

At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success.

We’re uniting science, technology, and talent to get ahead of disease together.

The Clinical Operations Asset Lead (COAL), Late Phase Lung Oncology is accountable for the operational strategy and delivery of complex global clinical programs across the asset lifecycle. As a key member of the Medicine Development Team, the COAL translates scientific strategy into executable operational plans, partnering across Clinical Development, Biostatistics and functional experts to enable informed asset decisions. This role provides strategic leadership to Study Delivery Teams and oversees delivery across multiple studies, indications and combinations, while retaining overall accountability for successful asset delivery.

• Own the clinical operational strategy and end-to-end delivery of the asset
  , from candidate commitment through development, late-phase delivery and lifecycle management.
• Shape the Clinical Development Plan and Integrated Evidence Plan
  , ensuring studies are operationally feasible, scientifically aligned and positioned for high-quality, timely delivery.
• Lead asset-level operational planning and scenario modelling
  , balancing timelines, cost, resources, quality and risk to inform governance decisions and optimize delivery.
• Define and oversee the asset resourcing strategy
  , including in sourcing/outsourcing decisions, vendor selection and oversight of external delivery partners.
• Provide strategic leadership across Study Delivery Teams
  , coordinating cross-functional expertise and acting as the senior escalation point for significant operational, quality and delivery issues.
• Drive asset-level risk management, quality and inspection readiness
  , embedding Quality by Design principles and ensuring effective mitigation of operational and GCP-related risks.
• Lead operational strategies across countries, patient engagement, diversity and study execution
  , bringing innovation, technology and external insights into asset delivery.
• Ensure robust financial, data and stakeholder governance
  , including accurate budget forecasting, operational data, regulatory submission contributions and effective communication across clinical operations and asset stakeholders.

We are seeking professionals with the following required skills and qualifications to help us achieve our goals

• Bachelor’s degree in life sciences, healthcare, business or a related field, or equivalent experience.
• Minimum of 10 years of pharmaceutical R&D or related industry experience.
• At least 3 years of experience as COAL (or similar role) in lung cancer indications
• 5 years + experience successfully managed global, complex programs with multiple studies
• Demonstrated experience with preparing for BLA filing (from early prep to actual filing) and BLA inspection readiness
• Deep therapeutic area expertise and solid knowledge of the lung treatment landscape and competitive environment

Preferred Qualification
If you have the following characteristics, it would be a plus

• Advanced degree (Master’s, PhD, PharmD, MD) in a relevant discipline.
• Day-to-day fluency in using AI to accelerate trial timelines, improve data quality, evidence assurance, and…